Literature DB >> 2117420

In vitro susceptibilities of oxacillin-resistant Staphylococcus aureus to dapsone and sulfamethoxazole alone and in combination with trimethoprim.

M W Lambertus1, R Y Kwok, M E Mulligan.   

Abstract

The in vitro activity of trimethoprim plus dapsone against oxacillin-resistant Staphylococcus aureus was comparable to that of trimethoprim plus sulfamethoxazole. Because of its different pharmacologic properties, dapsone may be a useful agent in combination with trimethoprim for the treatment of patients colonized with oxacillin-resistant S. aureus.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2117420      PMCID： PMC176001          DOI： 10.1128/AAC.34.7.1453

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Preferential uptake of sulphone by affected skin tissue of leprosy patients as detected by a tracer method.

Authors:  K R CHATTERJEE; R K PODDAR
Journal:  Nature       Date:  1956-10-13       Impact factor: 49.962

Review 2.  A review of therapeutic and hemolytic effects of dapsone.

Authors:  R L DeGowin
Journal:  Arch Intern Med       Date:  1967-08

3.  The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit.

Authors:  R W Haley; A W Hightower; R F Khabbaz; C Thornsberry; W J Martone; J R Allen; J M Hughes
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

4.  Studies on the in vitro development of drug resistance of Proteeae to sulfonamides, trimethoprim and combinations of a sulfonamide and trimethoprim.

Authors:  E Grunberg; G Beskid
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

Review 5.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546
  5 in total
  1 in total

1.  Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone.

Authors:  H H Locher; H Schlunegger; P G Hartman; P Angehrn; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.